First-line treatment of advanced non-small cell lung cancer with ALK rearrangement: state of the art and future development

References

• Stoica GE, Kuo A, Aigner A, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem. 2001.
   PubMed Web of Science ®Google Scholar
• Wellstein AT. A: midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002. doi:https://doi.org/10.1074/jbc.M205749200
   Google Scholar
• Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001.
   Web of Science ®Google Scholar
• Holla VR, Elamin YY, Bailey AM, et al. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud. 2017. DOI:https://doi.org/10.1101/mcs.a001115.
   Google Scholar
• Ou SI, Shirai K. Anaplastic Lymphoma Kinase (ALK) signaling in lung cancer. Adv Exp Med Biol. 2016. DOI:https://doi.org/10.1007/978-3-319-24223-1_9
   Google Scholar
• Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997;14:439-449.
   PubMed Web of Science ®Google Scholar
• Palmer RH, Vernersson E, Grabbe C, et al. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009. DOI:https://doi.org/10.1042/BJ20090387.
   Google Scholar
• Chia PL, Mitchell P, Dobrovic A, et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol. 2014. DOI:https://doi.org/10.2147/CLEP.S69718.
   Google Scholar
• Hofman P. ALK in Non-Small Cell Lung Cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. lai R, ed. Cancers (Basel). 2017. DOI:https://doi.org/10.3390/cancers9080107
   Google Scholar
• Zhao F, Xu M, Lei H, et al. Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis. PLoS One. 2015. DOI:https://doi.org/10.1371/journal.pone.0117333.
   Google Scholar
• Sabir SR, Yeoh S, Jackson G, et al. EML4-ALK variants: biological and molecular properties, and the implications for patients. Lai R, ed. Cancers (Basel). 2017. DOI:https://doi.org/10.3390/cancers9090118.
   Google Scholar
• Bayliss R, Choi J, Fennell DA, et al. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci. 2016. DOI:https://doi.org/10.1007/s00018-015-2117-6.
   Google Scholar
• Du X, Shao Y, Qin H, et al. ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC). Thorac Cancer. 2018. DOI:https://doi.org/10.1111/1759-7714.12613.
   Google Scholar
• Passaro A, Lazzari C, Karachaliou N, et al. Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. Onco Targets Ther. 2016. DOI:https://doi.org/10.2147/OTT.S98347.
   Google Scholar
• National comprehensive cancer network guidelines for NSCLC, version 6.2018; [cited Sept 2018] Available from:: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar
• Kazandjian D, Blumenthal GM, Chen H-Y, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist. 2014. DOI:https://doi.org/10.1634/theoncologist.2014-0241.
   Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013. Epub 2013 Jun 1. DOI:https://doi.org/10.1056/NEJMoa1214886.
   Google Scholar
• Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014. doi: https://doi.org/10.1056/NEJMoa1408440
   Google Scholar
• Wu YL, Lu S, Lu Y, et al. Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol. 2018. DOI:https://doi.org/10.1016/j.jtho.2018.06.012.
   Google Scholar
• Felip E, Orlov S, Park K, et al. ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J clin oncol. 2015. DOI:https://doi.org/10.1200/jco.2015.33.15_suppl.8060.
   Google Scholar
• Soria J-C, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017. doi: https://doi.org/10.1016/S0140-6736(17)30123-X.
   Google Scholar
• Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017. DOI:https://doi.org/10.1016/S0140-6736(17)30565-2.
   Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated alk-positive non–small-cell lung cancer. N Engl J Med. 2017. doi: https://doi.org/10.1056/NEJMoa1704795
   Google Scholar
• Ross Camidge D, Peters S, Mok T, et al. Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. J Clin Oncol. 2018. doi: https://doi.org/10.1200/JCO.2018.36.15_suppl.9043
   Google Scholar
• Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: A single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016. DOI:https://doi.org/10.1016/S1470-2045(16)30392-8.
   Google Scholar
• Bazhenova L, Gettinger SN, Langer CJ, et al. Brigatinib (BRG) in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): updates from a phase 1/2 trial. J Clin Oncol. 2017.
   Web of Science ®Google Scholar
• Kim D-W, Tiseo M, Ahn M-J, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase–positive non–small-cell lung cancer: A randomized, multicenter phase II trial. J Clin Oncol. 2017. DOI:https://doi.org/10.1200/JCO.2016.71.5904.
   Google Scholar
• Camidge DR, Kim DW, Tiseo M, et al. Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials. J Clin Oncol. 2018. DOI:https://doi.org/10.1200/JCO.2017.77.5841.
   Google Scholar
• Ross Camidge D, Kim HR, Ahn M-J, et al. Brigatinib versus crizotinib in ALK-positive non–small-cell lung cancer. N Engl J Med. 2018. doi: https://doi.org/10.1056/NEJMoa1810171.
   Google Scholar
• Zhu Q, Hu H, Weng D-S, et al. Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC. BMC Cancer. 2017. DOI:https://doi.org/10.1186/s12885-017-3405-3.
   Google Scholar
• Costa RB, Costa RLB, Talamantes SM, et al. Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer. Oncotarget. 2018. DOI:https://doi.org/10.18632/oncotarget.25154.
   Google Scholar
• Cho BC, Kim DW, Bearz A, et al. ASCEND-8: A randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with Anaplastic Lymphoma Kinase (ALK)-rearranged metastatic Non–small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2017. DOI:https://doi.org/10.1016/j.jtho.2017.07.005.
   Google Scholar
• Cho BC, Obermannová R, Bearz A, et al. Efficacy and updated safety of ceritinib (450 mg or 600 mg) with low-fat meal vs 750 mg fasted in ALK+ Metastatic NSCLC. J Thorac Oncol. 2017. DOI:https://doi.org/10.1016/j.jtho.2017.09.352.
   Google Scholar
• Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov. 2017. DOI:https://doi.org/10.1158/2159-8290.CD-16-1123.
   Google Scholar
• Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016. doi: https://doi.org/10.1158/2159-8290.CD-16-0596
   PubMedGoogle Scholar
• Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017. DOI:https://doi.org/10.1016/S1470-2045(17)30680-0.
   Google Scholar
• Horn L, Infante JR, Reckamp KL, et al. Ensartinib (X-396) in ALK-positive non–small cell lung cancer: results from a first-in-human phase I/II, multicenter study. Clin Cancer Res. 2018. DOI:https://doi.org/10.1158/1078-0432.CCR-17-2398.
   Google Scholar
• Woo CG, Seo S, Kim SW, et al. Differential protein stability and clinical responses of EML4 – ALK fusion variants to various ALK inhibitors in advanced ALK - rearranged non-small cell lung cancer. Ann Oncol. 2017. doi: https://doi.org/10.1093/annonc/mdw693.
   Google Scholar
• Moya-Horno I, Viteri S, Karachaliou N, et al. Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Ther Adv Med Oncol. 2018. DOI:https://doi.org/10.1177/1758834017745012.
   Google Scholar
• Ahn MJ, Sun JM, Lee SH, et al. EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opin Drug Saf. 2017. DOI:https://doi.org/10.1080/14740338.2017.1300656.
   Google Scholar